Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
16 participants
INTERVENTIONAL
2020-05-29
2021-02-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Binding and Effects of Lu AG06466 in the Brain of Healthy Men
NCT05219838
A Brain Imaging PET Study of [11C]-Lu AF90103 in Healthy Adult Male Participants
NCT05306366
A Study in Healthy Men to Investigate Uptake and Distribution of Lu AF88434 in the Brain
NCT04538014
A Brain Imaging PET Study of [11C]-Lu AF88370 in Healthy Adult Male Participants
NCT05320302
Characterization of Cerebral Tau Aggregates With 18F-RO6958948 PET in the ALFA Population
NCT04482660
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PET scans will be used to quantify MAGL occupancy
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part A Single doses
Lu AG06466 in fast and fed state
Lu AG06466
capsules, orally
Part B Repeated doses
Lu AG06466 after light meal
Lu AG06466
capsules, orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lu AG06466
capsules, orally
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* body mass index ≥18.5 and ≤27 kg/m2.
* waist circumference ≤94 cm.
* The subject has a normal sMRI performed during the screening period.
* The subject is suitable for radial artery blood sampling and cannulation as demonstrated by the Allen test.
* Subject must be healthy as assessed using detailed medical history, laboratory tests, and physical examination.
* The subject must make use of contraception.
Exclusion Criteria
18 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
H. Lundbeck A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UZ Leuven campus Gasthuisberg
Leuven, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
18454A
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.